PDF(Sci-hub)
Abstract：
OBJECTIVE: To evaluate the characteristics of macular retinal and subfoveal choroidal changes in patients already on taxane-based therapy by the help of spectral domain optical coherence tomograpy (SD-OCT) and determine the incidence of taxane- related cystoid macular edema (CME).
METHODS: In this cross-sectional case-control study, 202 patients who received taxane-based therapy due to treatment of various cancer and age and sex-matched 200 healthy control subjects were examined. Only patients who received at least 4 cycles of taxane-based therapy were taken into consideration for the taxane group. Taxane-based therapy was further divided into two subgroups; paclitaxel group (149 patients) and docetaxel group (53 patients). Central macular thickness (CMT) and central subfoveal choroidal thickness (CCT) were measured just once during their ongoing chemotherapy using SD-OCT and enhanced-depth imaging (EDI) OCT by Heidelberg OCT by a single examiner.
RESULTS: Patients received a median of 7 cycles (range, 4-26) of paclitaxel or docetaxel and received a total cumulative dose of 852.81 ± 368.82 mg/m2 (range, 300-2310 mg/m2). Though the mean CMT was significantly thicker in the taxane group (224.9 ± 28.4 µm) than the healthy control group (215.9 ± 19.7 µm), there was no statistically significant difference between the paclitaxel (225.3 ± 28.2 µm) and docetaxel (224.2 ± 20.1 µm) groups. On the other hand, the CCT was not statistically significant different between the taxane versus control eyes and paclitaxel versus docetaxel patients. Taxane-related CME was detected only in one patient on paclitaxel. Overall, incidence of taxane-related maculopathy was 0.5% (1/202) of all patients in the taxane group.
CONCLUSIONS: In our group of taxane receiving patients, incidence of taxane-related CME was 0.5%. In light of our study, we believe that clinicians should be alert on the occurence of taxane-related CME and carefully scrutinize the patients whenever any suspicion is arisen.
METHODS: In this cross-sectional case-control study, 202 patients who received taxane-based therapy due to treatment of various cancer and age and sex-matched 200 healthy control subjects were examined. Only patients who received at least 4 cycles of taxane-based therapy were taken into consideration for the taxane group. Taxane-based therapy was further divided into two subgroups; paclitaxel group (149 patients) and docetaxel group (53 patients). Central macular thickness (CMT) and central subfoveal choroidal thickness (CCT) were measured just once during their ongoing chemotherapy using SD-OCT and enhanced-depth imaging (EDI) OCT by Heidelberg OCT by a single examiner.
RESULTS: Patients received a median of 7 cycles (range, 4-26) of paclitaxel or docetaxel and received a total cumulative dose of 852.81 ± 368.82 mg/m2 (range, 300-2310 mg/m2). Though the mean CMT was significantly thicker in the taxane group (224.9 ± 28.4 µm) than the healthy control group (215.9 ± 19.7 µm), there was no statistically significant difference between the paclitaxel (225.3 ± 28.2 µm) and docetaxel (224.2 ± 20.1 µm) groups. On the other hand, the CCT was not statistically significant different between the taxane versus control eyes and paclitaxel versus docetaxel patients. Taxane-related CME was detected only in one patient on paclitaxel. Overall, incidence of taxane-related maculopathy was 0.5% (1/202) of all patients in the taxane group.
CONCLUSIONS: In our group of taxane receiving patients, incidence of taxane-related CME was 0.5%. In light of our study, we believe that clinicians should be alert on the occurence of taxane-related CME and carefully scrutinize the patients whenever any suspicion is arisen.
摘要：
目的：通过谱域光学相干断层扫描（SD-OCT）评估已经接受紫杉烷治疗的患者的黄斑视网膜和中心凹下脉络膜改变的特征，并确定紫杉烷相关性黄斑囊样水肿（CME）的发生率。
方法：在这项横断面病例对照研究中，检查了202例因治疗各种癌症而接受基于紫杉烷的治疗的患者以及年龄和性别匹配的200名健康对照受试者。紫杉烷组仅考虑接受至少4个周期的紫杉烷治疗的患者。基于紫杉烷的治疗进一步分为两个亚组：紫杉醇组（149例患者）和多西他赛组（53例患者）。中央黄斑厚度（CMT）和中央凹下脉络膜厚度（CCT）在其正在进行的化疗期间使用SD-OCT和海德堡OCT由单个检查者进行的增强深度成像（EDI）OCT测量一次。
结果：患者接受了7个周期的中位数（范围，4-26）的紫杉醇或多西他赛，并接受总累积剂量为852.81±368.82mg/m2（范围，300-2310mg/m2)。尽管紫杉烷组的平均CMT（224.9±28.4µm）明显高于健康对照组（215.9±19.7µm），紫杉醇组(225.3±28.2µm)和多西他赛组(224.2±20.1µm)之间无统计学差异.另一方面,紫杉烷与对照组患者,紫杉醇与多西他赛患者的CCT无统计学差异.仅在一名接受紫杉醇治疗的患者中检测到紫杉烷相关CME。总的来说,紫杉烷组所有患者的紫杉烷相关性黄斑病变发生率为0.5%(1/202).
结论：在我们接受紫杉烷治疗的患者组中，紫杉烷相关CME的发生率为0.5%。根据我们的研究,我们认为,临床医生应警惕紫杉烷相关CME的发生,并在出现任何怀疑时仔细检查患者.
方法：在这项横断面病例对照研究中，检查了202例因治疗各种癌症而接受基于紫杉烷的治疗的患者以及年龄和性别匹配的200名健康对照受试者。紫杉烷组仅考虑接受至少4个周期的紫杉烷治疗的患者。基于紫杉烷的治疗进一步分为两个亚组：紫杉醇组（149例患者）和多西他赛组（53例患者）。中央黄斑厚度（CMT）和中央凹下脉络膜厚度（CCT）在其正在进行的化疗期间使用SD-OCT和海德堡OCT由单个检查者进行的增强深度成像（EDI）OCT测量一次。
结果：患者接受了7个周期的中位数（范围，4-26）的紫杉醇或多西他赛，并接受总累积剂量为852.81±368.82mg/m2（范围，300-2310mg/m2)。尽管紫杉烷组的平均CMT（224.9±28.4µm）明显高于健康对照组（215.9±19.7µm），紫杉醇组(225.3±28.2µm)和多西他赛组(224.2±20.1µm)之间无统计学差异.另一方面,紫杉烷与对照组患者,紫杉醇与多西他赛患者的CCT无统计学差异.仅在一名接受紫杉醇治疗的患者中检测到紫杉烷相关CME。总的来说,紫杉烷组所有患者的紫杉烷相关性黄斑病变发生率为0.5%(1/202).
结论：在我们接受紫杉烷治疗的患者组中，紫杉烷相关CME的发生率为0.5%。根据我们的研究,我们认为,临床医生应警惕紫杉烷相关CME的发生,并在出现任何怀疑时仔细检查患者.
